Benzyl (3R,4S)-3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate is a key intermediate of upatinib. At the beginning of 2018, the oral Jak1 selective inhibitor upadacitinib (abt-494), developed by abbvie in the United States once every day for the treatment of adult moderate and severe atopic dermatitis, was recognized as a breakthrough therapy by FDA.